Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cigna

GE HealthCare Technologies Inc

HCA Healthcare

Intuitive Surgical

Eli Lilly

McKesson

There are a whole host of reasons to invest in healthcare stocks over the long term. The United States has an aging population.

Healthy Profits: 7 Healthcare Stocks to Build a Lifetime of Wealth

Infosys

The overall stock market has been reeling over the last week or so. The S&P 500 index and NASDAQ have fallen by 4% and 6%, respectively, since July 16 due to uncertainty regarding the future of artificial intelligence.

3 Stocks With the Most Recent 52-Week Highs

BIRMINGHAM, England--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has been 510k cleared, following US Food and Drug Administration (FDA) requirements, to market its Optilite® Freelite® assays' claim for the evaluation of monoclonal gammopathy of undetermined significance (MGUS). MGUS affects an estimated 3% of the U.S. population over 50 and is a lifelong condition where abnormal monoclonal proteins are found in a patient's blood.1 Once.

Thermo Fisher Scientific Announces Extended 510k Clearance of Freelite Assays for Evaluation of MGUS, a Precursor to Multiple Myeloma

Thermo Fisher Scientific is a top dividend growth stock with a complex post-pandemic situation. Recent earnings show promising growth in key segments, despite a high valuation. Strategic investments in R&D and acquisitions position TMO for continued long-term success.

Thermo Fisher: A Dividend Investor's Lab Partner For Growth And Stability

DuPont de Nemours

Veeco Instruments

Given the expanding size of the nanotechnology industry, buying nanotechnology stocks with a very low-risk profile is possible. Electronics is one of the most important sectors that applies nanotechnology.

3 Nanotechnology Stocks With Microscopic Risk

CHICAGO--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. will showcase its broad diagnostics portfolio and host a series of customer-led workshops and presentations that highlight industry developments and the company's latest innovations during the Association for Diagnostics & Laboratory Medicine Conference (ADLM) July 28-Aug. 1, 2024, in Chicago, Ill. The company's conference booth (#2213) has also been designed as a “Story Tunnel” to lead visitors along a journey of research and clinical.

Thermo Fisher Scientific Showcases Diagnostics Innovation Across Therapeutic Areas at ADLM 2024

Thermo Fisher Scientific is finally starting to show signs of growth after getting through the headwind of declining covid-related business. Growth sources include increased business in China, completion of the Olink deal, and an increase in the number of clinical trials. Financial model updates and valuation analysis suggest the stock is currently priced at fair value, making it a Hold for now.

Thermo Fisher Scientific: Microscopic Signs Of Growth Emerging

The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Laboratory Products and Biopharma Services revenues disappoints. However, margins expand in the second quarter.

Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View

Thermo Fisher Scientific Inc. (NYSE:TMO ) Q2 2024 Earnings Conference Call July 24, 2024 8:30 AM ET Company Participants Rafael Tejada - Vice President Investor Relations Marc Casper - Chairman, President and Chief Executive Officer Stephen Williamson - Senior Vice President and Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Jack Meehan - Nephron Research Rachel Vatnsdal - JPMorgan Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Puneet Souda - Leerink Partners Dan Arias - Stifel Operator Good morning, ladies and gentlemen and welcome to the Thermo Fisher Scientific 2024 Second Quarter Conference Call. [Operator Instructions] I would like to introduce our moderator for the call, Mr.

Thermo Fisher Scientific Inc. (TMO) Q2 2024 Earnings Call Transcript

The headline numbers for Thermo Fisher (TMO) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Thermo Fisher (TMO) Reports Q2 Earnings: What Key Metrics Have to Say

Thermo Fisher Scientific (TMO) reported better second-quarter earnings than analysts had expected Wednesday, and also raised its projections for the full fiscal year.

Thermo Fisher Q2 Earnings Beat Estimates, Guidance Lifted

Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.37 per share, beating the Zacks Consensus Estimate of $5.13 per share. This compares to earnings of $5.15 per share a year ago.

Thermo Fisher Scientific (TMO) Q2 Earnings and Revenues Top Estimates

Thermo Fisher on Wednesday raised its annual profit outlook and posted a better-than-expected second-quarter profit, banking on improved demand for its tools and services used in clinical trials.

Thermo Fisher lifts profit forecast as biotech demand shows signs of improvement

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29, 2024. Second Quarter 2024 Highlights Second quarter revenue was $10.54 billion. Second quarter GAAP diluted earnings per share (EPS) increased 15% to $4.04. Second quarter adjusted EPS increased 4% to $5.37. Advanced our proven growth strategy, launching a range of high-impact, innovative new products during t.

Thermo Fisher Scientific Reports Second Quarter 2024 Results

Align Technology

Boston Scientific

Edwards Lifesciences

Here is a sneak peek into how four MedTech bigshots, BSX, TMO, ALGN and EW, are expected to fare in their second-quarter results, slated to be released tomorrow.

Can These 4 MedTech Stocks Hit Targets This Earnings Season?

Analog Devices

NVIDIA

Nanotech stocks remain at the forefront of every tech-savvy investor's portfolio, considering the predicted worldwide nanotechnology market size in 2024 is $91.18 billion. Analysts project market size will reach $332.73 billion by 2032, with a CAGR of 17.6%.

3 Nantotech Stocks to Bet On for Market-Crushing Returns

Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "Medical Refrigerators - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Medical Refrigerators is estimated at US$4.4 Billion in 2023 and is projected to reach US$7.1 Billion by 2030, growing at a CAGR of 6.9% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. Key Insights:

$7.1 Billion Medical Refrigerators Market and Industry Insights, 2024-2030, Featuring Strategic Analysis of 42 Major Players, Including Godrej, Haier Biomedical, Thermo Fisher Scientific

Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Thermo Fisher Scientific (TMO) to Report a Decline in Earnings: What to Look Out for

Strength in Analytical Instrument and Laboratory Products and Services segments is likely to have driven Thermo Fisher's (TMO) second-quarter 2024 performance.

Here's How Thermo Fisher (TMO) is Placed Ahead of Q2 Earnings

Alcon Inc. - Registered Shares

DexCom

Hologic

DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific are included in this Analyst Blog.

The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific

Stocks tend to sell off after they reach resistance. They also tend to rally off of support.

Stock Of The Day: How To Predict Thermo Fisher Scientific Trend Reversals

We have narrowed our search to five Medical Instruments stocks. These are: DXCM, TMO, ISRG, ALC, HOLX.

Buy 5 Medical Devices Stocks to Enhance Your Portfolio in 2H

Thermo Fisher (TMO) announces a partnership with the National Cancer Institute for the myeloMATCH precision medicine umbrella trial to fuel research regarding new treatments for AML and MDS.

Thermo Fisher (TMO) Inks New Partnership for myeloMATCH Trial

Investors with an interest in Medical - Instruments stocks have likely encountered both Thermo Fisher Scientific (TMO) and Idexx Laboratories (IDXX). But which of these two stocks is more attractive to value investors?

TMO or IDXX: Which Is the Better Value Stock Right Now?

WALTHAM, Mass.--(BUSINESS WIRE)--To help accelerate research into new treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is partnering with the National Cancer Institute (NCI) – part of the National Institutes of Health – on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial. By testing patients' bone marrow and blood for certain genetic biomarkers u.

News for Thermo Fisher Scientific Stock (TMO)